change control – Page 27

Potential nitrosamine source identified during risk assessment – CAPA for nitrosamine findings

Identifying Potential Nitrosamine Sources: An Actionable CAPA Playbook Nitrosamine contamination has emerged as a significant concern in pharmaceutical manufacturing, particularly with raw materials and excipients. These impurities can pose risks…

Nitrosamine risk assessment incomplete during submission support – CAPA for nitrosamine findings

Addressing Incomplete Nitrosamine Risk Assessments During Regulatory Submissions The pharmaceutical industry faces increasing scrutiny regarding nitrosamine contamination in products, particularly in the context of regulatory submissions. When nitrosamines are detected…

Nitrosamine risk assessment incomplete during submission support – risk mitigation and control strategy

Mitigating Incomplete Nitrosamine Risk Assessments During Submission Support Nitrosamines are a significant concern in pharmaceutical manufacturing, especially regarding regulatory submission support. Incomplete risk assessments related to nitrosamines can lead to…

Analytical method sensitivity questioned during submission support – CAPA for nitrosamine findings

Managing Analytical Method Sensitivity Issues During Submission Support In the pharmaceutical industry, facing questions regarding the sensitivity of analytical methods during the submission process can complicate compliance and risk management…

Regulatory query on nitrosamines during ongoing surveillance – risk mitigation and control strategy

Effective Strategies for Mitigating Nitrosamine Regulatory Queries during Ongoing Surveillance Nitrosamines have emerged as a critical concern in pharmaceutical manufacturing due to their potential carcinogenic effects. Regulatory authorities like FDA,…

Nitrosamine risk assessment incomplete during submission support – preventing product recall

Navigating Incomplete Nitrosamine Risk Assessments During Submission Support to Prevent Product Recalls As the pharmaceutical industry faces heightened scrutiny regarding nitrosamine contamination, the potential for incomplete nitrosamine risk assessments during…

Nitrosamine risk assessment incomplete during regulatory inspection – inspection-ready justification

Navigating Incomplete Nitrosamine Risk Assessments During Regulatory Inspections Nitrosamines pose significant risks to pharmaceutical quality, necessitating rigorous material management protocols. Incomplete risk assessments for nitrosamines during regulatory inspections can result…

Tag: change control

Potential nitrosamine source identified during risk assessment – CAPA for nitrosamine findings

Nitrosamine risk assessment incomplete during submission support – CAPA for nitrosamine findings

Nitrosamine risk assessment incomplete during submission support – risk mitigation and control strategy

Analytical method sensitivity questioned during submission support – CAPA for nitrosamine findings

Regulatory query on nitrosamines during ongoing surveillance – risk mitigation and control strategy

Nitrosamine risk assessment incomplete during submission support – preventing product recall

Nitrosamine risk assessment incomplete during regulatory inspection – inspection-ready justification

Nitrosamine risk assessment incomplete during supplier audit – preventing product recall

Analytical method sensitivity questioned during ongoing surveillance – CAPA for nitrosamine findings

Nitrosamine risk assessment incomplete during regulatory inspection – CAPA for nitrosamine findings

Supplier nitrosamine control weak during risk assessment – risk mitigation and control strategy

Nitrosamine risk assessment incomplete during regulatory inspection – preventing product recall